Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Lulama Rhoda Molife"'
Publikováno v:
Expert Opinion on Investigational Drugs. 20:1293-1304
There are clear preclinical data that support the involvement of the insulin-like growth factor (IGF) signaling pathway in oncogenesis and cancer progression. Such evidence has led to the design and conduct of drug development programs targeting the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95a6a47c8f896d5319137f47db1f161b
https://doi.org/10.1517/13543784.2011.602630
https://doi.org/10.1517/13543784.2011.602630
Autor:
Martin Gutierrez, Axel Walther, Rod A. Humerickhouse, M. Puglisi, Montserrat Blanco, Jianning Yang, Maja J.A. de Jonge, David Cosgrove, Lulama Rhoda Molife, Catherine Franklin, Todd A. Busman, Mack Mabry, Ferry A.L.M. Eskens, Kirsty Moran, Leni van Doorn
Publikováno v:
Molecular Cancer Therapeutics. 10:A92-A92
Background: Navitoclax (N; ABT-263) is a first-in-class orally available Bcl-2 protein inhibitor that in vitro and in vivo potentiates docetaxel (D) activity across a variety of solid tumor types. This ongoing phase I study evaluates the maximum tole
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1aa1ea29f00a51c6da169699683bbb21
https://doi.org/10.1158/1535-7163.targ-11-a92
https://doi.org/10.1158/1535-7163.targ-11-a92